IRadimed's Q4 revenue and EPS rise, declares higher dividend

Overview

• MRI-compatible device maker's Q4 revenue rose 17% yr/yr

• Q4 non-GAAP EPS increased 23% yr/yr

• Company declared quarterly dividend increase to $0.20 per share

Outlook

• IRadimed expects Q1 2026 revenue between $21 mln and $22 mln

• Company projects full-year 2026 revenue between $91 mln and $96 mln

• IRadimed anticipates Q1 2026 GAAP EPS between $0.39 and $0.43

Result Drivers

• UNIT SHIPMENTS - Successful shipment of 3870 units of next-gen MRI-compatible IV infusion pump drove Q4 revenue growth

• EMPLOYEE CONTRIBUTION - Co attributed success to employee dedication in clearing FDA 510k requirements and facility transition

• DIVIDEND INCREASE - Co increased quarterly cash dividend to $0.20 per share, reflecting confidence in business outlook

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for IRadimed Corp is $99.00, about 3.2% above its February 9 closing price of $95.97

• The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 37 three months ago

Press Release: ID:nGNX90952F

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.